Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Flexion Therapeutics Inc (NASDAQ:FLXN)

15.53
Delayed Data
As of May 27
 -1.70 / -9.87%
Today’s Change
7.56
Today|||52-Week Range
29.09
-19.41%
Year-to-Date
2 Sizzling-Hot Biotech Stocks to Buy
May 27 / MotleyFool.com - Paid Partner Content
Flexion (FLXN) Zilretta Gets Positive FDA Guidance; Stock Up
May 27 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close17.23
Today’s open16.86
Day’s range14.67 - 16.88
Volume1,046,628
Average volume (3 months)313,576
Market cap$335.0M
Dividend yield--
Data as of 3:59pm ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)-9.14%
Earnings growth (this year)-36.28%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book3.22

Competitors

 Today’s
change
Today’s
% change
RGNXRegenxbio Inc+0.33+2.70%
AMRNAmarin Corporation P...+0.03+1.64%
ARWRArrowhead Pharmaceut...+0.05+0.86%
ENZEnzo Biochem Inc-0.07-1.12%
Data as of 4:02pm ET, 05/27/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$0.64
Annual revenue (last year)$0.00
Annual profit (last year)-$46.3M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Michael D. Clayman
Chief Financial Officer
Frederick W. Driscoll
Corporate headquarters
Burlington, Massachusetts

Forecasts

Partner Offers

Search for Jobs